Case Report
Published: 21 May, 2025 | Volume 9 - Issue 1 | Pages: 001-002
Bruxism, characterized by involuntary, repetitive jaw-muscle activity including clenching and grinding of teeth, can lead to significant dental and muscular complications. Conventional treatments—such as occlusal splints and behavioral therapy-may not fully address muscular hyperactivity. Botulinum toxin type A (BoNT-A), a neurotoxin that inhibits acetylcholine release at neuromuscular junctions, has emerged as a promising therapeutic option. This article reviews clinical studies regarding the efficacy of BoNT-A injections into masticatory muscles for bruxism management, with a focus on clinical outcomes, safety, and practical considerations.
Read Full Article HTML DOI: 10.29328/journal.jcad.1001047 Cite this Article Read Full Article PDF
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."